Literature DB >> 10223227

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.

M Nakajima1, H Sawada, Y Yamada, A Watanabe, M Tatsumi, J Yamashita, M Matsuda, T Sakaguchi, T Hirao, H Nakano.   

Abstract

BACKGROUND: The c-met and the c-erb B-2 protooncogenes belong to a family of tyrosine kinase growth factor receptors. Abnormalities of these oncogenes and protein products have been reported in several cancers. The authors investigated the correlation between clinical factors and amplification or overexpression of the c-met and/or c-erb B-2 gene in Japanese patients with gastric carcinoma patients, with a focus on prognostic significance.
METHODS: Amplification and overexpression of c-met and c-erb B-2 were investigated retrospectively in 128 gastric carcinoma patients by using immunohistochemistry and Southern blot hybridization. Survival analysis was performed with the Kaplan-Meier test, and the log rank test was used for statistical analysis.
RESULTS: Overexpression of c-met and c-erb B-2 was observed in 46.1% and 16.4% of gastric carcinoma cases, respectively. Gene amplification of c-met and c-erb B-2 was detected in 10.2% and 11.7% of gastric carcinoma cases, respectively. Amplification and overexpression of c-met were correlated significantly with depth of tumor invasion and lymph node metastasis, whereas amplification and overexpression of c-erb B-2 were correlated significantly with histologic type. The survival rate of patients with amplification and/or overexpression of c-met or c-erb B-2 was significantly poorer than that of patients with no amplification or overexpression. Multivariate analysis revealed that c-met overexpression and lymph node metastasis were independent prognostic factors.
CONCLUSIONS: These data suggest that overexpression and/or gene amplification of c-met and c-erb B-2 may be prognostic factors in gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223227     DOI: 10.1002/(sici)1097-0142(19990501)85:9<1894::aid-cncr3>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  181 in total

1.  Cuirasse skin metastases secondary to gastric adenocarcinoma.

Authors:  Sara López-Tarruella Cobo; Fernando Moreno Antón; Javier Sastre; J A López García-Asenjo; A Torres; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

2.  The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein.

Authors:  Christine Rebischung; Raphaëlle Barnoud; Laetitia Stéfani; Jean-Luc Faucheron; Mireille Mousseau
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

3.  Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma.

Authors:  T Horikawa; T S Sheen; H Takeshita; H Sato; M Furukawa; T Yoshizaki
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 4.  ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors:  William H Fiske; David Threadgill; Robert J Coffey
Journal:  Exp Cell Res       Date:  2008-11-07       Impact factor: 3.905

5.  Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis.

Authors:  Andreas Krieg; Billur Baseras; Monika Tomczak; Pablo Emilio Verde; Nikolas Hendrik Stoecklein; Wolfram Trudo Knoefel
Journal:  Mol Biol Rep       Date:  2013-08-15       Impact factor: 2.316

6.  Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.

Authors:  Duminda Subasinghe; Sivasuriya Sivaganesh; Ananthi Samarsekera; Mariyan Priyanthi Kumarasinghe; Dharmabandhu Nandadeva Samarasekera; Menaka Dilani Samarwickrema Lokuhetty
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

Review 7.  HER2 directed therapy for gastric/esophageal cancers.

Authors:  Elizabeth Won; Yelena J Janjigian; David H Ilson
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 8.  Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Authors:  Y Zhang; S Doshi; M Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-05-26       Impact factor: 4.335

Review 9.  New advances in targeted gastric cancer treatment.

Authors:  Daniela Cornelia Lazăr; Sorina Tăban; Marioara Cornianu; Alexandra Faur; Adrian Goldiş
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 10.  Chemotherapy for metastatic gastric cancer: past, present, and future.

Authors:  Atsushi Ohtsu
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.